CAJ | 학술논문

目的：评价榄香烯联合替吉奥/奥沙利铂方案治疗复发及转移性胃癌的临床疗效和不良反应。方法选择我院2008年3月至2012年4月收治的晚期胃癌患者38例，随机分为榄香烯+替吉奥+奥沙利铂治疗组（实验组）（n=19）：及奥沙利铂联合 ELF（足叶乙甙+亚叶酸钙+5-氟尿嘧啶）治疗组（对照组）（n=19）。比较两组的治疗疗效和不良反应发生率。结果实验组部分缓解（PR）8例，病情稳定（SD）6例，病情进展（PD）5例，有效率（CR + PR）为42.10%，疾病控制率（CR + PR + SD）为73.68%。疾病进展时间（TTP）8.3个月，中位生存时间（MST）10.7个月。而对照组 PR6例，SD 5例，PD 8例，有效率为31.58%，疾病控制率57.59%，TPP 7.1个月，MST 为8.2个月。不良反应主要表现为白细胞的减少。临床症状及生活质量，实验组显著改善，两组比较有显著差异（P<0.01）。实验组 CD4/CD8比值， NK 细胞活性及 CD3、CD4、CD8阳性细胞百分率等免疫指标显著升高，两组之间存在显著性差异（P<0.05）。结论香烯联合替吉奥/奥沙利铂联合化疗治疗复发及转移性胃癌可以增强疗效，降低放、化疗的不良反应。。
목적：평개람향희연합체길오/오사리박방안치료복발급전이성위암적림상료효화불량반응。방법선택아원2008년3월지2012년4월수치적만기위암환자38례，수궤분위람향희+체길오+오사리박치료조（실험조）（n=19）：급오사리박연합 ELF（족협을대+아협산개+5-불뇨밀정）치료조（대조조）（n=19）。비교량조적치료료효화불량반응발생솔。결과실험조부분완해（PR）8례，병정은정（SD）6례，병정진전（PD）5례，유효솔（CR + PR）위42.10%，질병공제솔（CR + PR + SD）위73.68%。질병진전시간（TTP）8.3개월，중위생존시간（MST）10.7개월。이대조조 PR6례，SD 5례，PD 8례，유효솔위31.58%，질병공제솔57.59%，TPP 7.1개월，MST 위8.2개월。불량반응주요표현위백세포적감소。림상증상급생활질량，실험조현저개선，량조비교유현저차이（P<0.01）。실험조 CD4/CD8비치， NK 세포활성급 CD3、CD4、CD8양성세포백분솔등면역지표현저승고，량조지간존재현저성차이（P<0.05）。결론향희연합체길오/오사리박연합화료치료복발급전이성위암가이증강료효，강저방、화료적불량반응。。
Objective To evaluate the efficacy and and side effect of elemene injection combined S-1 plus oxaliplatin regimen in the treatment of patients with advanced gastric carcinoma. Methods From March 2008 to April 2012, 38 patients with advanced gastric carcinoma fulfilled the inclusion criteria and were randomly divided into two groups: S-1 plus oxaliplatin group (test group)(n=19) and oxaliplatin + calcium folinate +5-FU + etoposide group (control group) (n=19). All patients received at least two cycle therapy. The efficacy and toxicity were evaluated after 2 cycles of treatment. Results In test group, Eight patient s achieved partial response(PR), six patient s had stable disease (SD), and five patient s had progression disease (PD). The overall response rate was 42.10%. The clinical beneficial response was 73.68%. The TTP was 8.3 months. The MST was 10.7 months. In control group, PR 6 cases, SD 5 cases, PD 8 cases, The overall response rate was 31.58%. The clinical beneficial response was 57.59%. TPP was 7.1 months. MST was 8.2 months. The major toxicities included myelosuppression,gastrointestinal reaction and peripheral nerve toxicity. The Ⅲ/Ⅳadverse reaction in test group significant lower than control group (P<0.01). The life quality and clinical symptom of the patients in test group were improved more significantly than those in control group (P<0.01), the value of CD3, CD4, CD3/CD4 and NK in test group were significantly higher than in control group (P<0.05). Conclusions The elemene injection combined S-1 plus oxaliplatin have better clinical efficacy and acceptable safety in patients with advanced gastric cancer, enhance the immune function and improve life quality. It’s worthy to be recommended.